An Evaluation of Changes in the Relationships Between Fatigue and Molecular Mechanisms in Cancer Patients Receiving Curative-Intent Combined Chemotherapy and Radiation Therapy (CCRT)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer
- Sponsor
- University of California, San Francisco
- Enrollment
- 125
- Locations
- 1
- Primary Endpoint
- Measure associations between changes in cancer-related fatigue (CRF) and changes in gene expression over time
- Status
- Recruiting
- Last Updated
- 7 months ago
Overview
Brief Summary
Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.
Detailed Description
Primary Objective For mean, morning and evening CRF: Aim 1. Evaluate for associations between phenotypic characteristics and initial levels and the trajectories of CRF. Aim 2. Evaluate for associations between changes in CRF severity and changes in gene expression levels prior to the initiation and at the end of CCRT. Aim 3. Evaluate for associations between changes in CRF severity and changes in circulating free cytokine levels prior to the initiation and at the end of CCRT. Aim 4. Develop and assess predictive models for CRF severity midway, at the end of, and at least six months post-CCRT using demographic, clinical, and molecular characteristics collected prior the initiation of CCRT. Secondary Objectives For the commonly co-occurring symptom of chemotherapy-induced peripheral neuropathy (CIPN): Secondary Aim 5. Evaluate for associations between phenotypic characteristics and initial levels and the trajectories of CIPN. Secondary Aim 6. Evaluate for associations between changes in CIPN severity and changes in gene expression levels prior to the initiation and at the end of CCRT. Secondary Aim 7. Evaluate for associations between changes in CIPN severity and changes in circulating free cytokine levels prior to the initiation and at the end of CCRT. Secondary Aim 8. Develop and assess predictive models for CIPN severity midway, at the end of, and at least six months post-CCRT using demographic, clinical, and molecular characteristics collected prior the initiation of CCRT. Exploratory Aim 1 - Evaluate the feasibility of the protocol for the collection of stool samples. Exploratory Aim 2 - Evaluate the feasibility of processing and storing stool samples. Exploratory Aim 3 - Evaluate the feasibility of processing and storing performing blood samples and performing Cytometry by time of flight (CyTOF) assays.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the month except surgery or inductive Chemotherapy (CTX).
- •Participants receiving \>= 15 fractions.
- •Participants is male or female and is \>18 years of age on the day of signing the informed consent.
- •Ability to understand a written informed consent document.
- •Able and willing to complete all of the study questionnaires and provide blood and stool samples prior to, midway, and following the completion of treatment.
- •Willing to have medical records reviewed for clinical information.
- •Able to read, write and understand English or Spanish.
Exclusion Criteria
- •Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).
Outcomes
Primary Outcomes
Measure associations between changes in cancer-related fatigue (CRF) and changes in gene expression over time
Time Frame: Up to 34 weeks
Association between phenotypic characteristics and initial levels and trajectories of CRF severity will be assessed using a hierarchical linear model (HLM) approach.
Measure associations between changes in CRF and changes in cytokine levels over time
Time Frame: Up to 34 weeks
Association between changes in CRF severity and biomarker levels prior to the initiation and at the end of CCRT. Linear regression will be used to evaluate for associations between fatigue changes and biomarker levels at baseline controlling for covariates identified in the initial primary outcome. Adjustments for multiple comparisons will be conducted using the Benjamini-Hochberg (BH) procedure at a false discovery rate (FDR) of 10%.
Measure associations between changes in CRF and changes in gene expression over time
Time Frame: Up to 34 weeks
Association between changes in CRF severity and gene expression prior to the initiation and at the end of CCRT. Linear regression will be used to evaluate for associations between fatigue changes and biomarker levels at baseline controlling for covariates identified in the initial primary outcome. Adjustments for multiple comparisons will be conducted using the Benjamini-Hochberg (BH) procedure at a false discovery rate (FDR) of 10%.
Evaluate the predictive utility of gene expression and cytokine data
Time Frame: Up to 34 weeks
A validated prediction model of CRF severity will be generated using machine learning (ML) methods to minimize the error between predicted and observed levels of fatigue midway through CCRT, at the completion of CCRT, and at least six months following the completion of CCRT. Evaluation of common ML algorithms for prediction accuracy and evaluation of model performance as compared to simple linear regression. Separate training and testing sets will be created, cross-validated, and repeated and impact of each variable will be determined.
Secondary Outcomes
- Evaluate for associations between changes in chemotherapy-induced peripheral neuropathy (CIPN) and changes in gene expression(Up to 34 weeks)
- Evaluate for associations between changes in CIPN and changes in cytokine levels(Up to 34 weeks)
- Evaluate the predictive utility of gene expression and severity of CIPN(Up to 34 weeks)
- Evaluate the predictive utility of cytokine levels and severity of CIPN(Up to 34 weeks)
- Evaluate the predictive model of severity of CIPN(Up to 34 weeks)